Research news

Joan Montero and colleagues in Boston suggest a new strategy for melanoma patients

IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future.

Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.

Read more…

Other news

IBEC receives the FEI award for its support to innovation

Yesterday, the Innovative Companies Forum (“FEI”, in Spanish) celebrated the seventh edition of the 2019 “Innovation Awards”. The awards ceremony, which aims to highlight the commitment to innovation of organizations, companies and researchers, recognized the Institute for Bioengineering of Catalonia’s (or “IBEC”) “Innovation Support Agency”. David Badia, executive director of the institute, received the award during the ceremony, which took place in Madrid.

During his acceptance speech, Badia noted that IBEC is accredited as a Severo Ochoa Centre of Excellence and is dedicated to the field of bioengineering, with the objective not only to study, but to also promote the research’s application in the field of medicine, health and the improvement of people’s quality of life.

Read more…